Adrenomedullin in Cancer: Tumor Growth Promoter, Angiogenesis Driver, and Potential Drug Target

What the researchers found

Adrenomedullin is overexpressed in many cancers where it promotes tumor growth, drives angiogenesis (tumor blood vessel formation), and may suppress anti-tumor immunity — positioning it as a multi-mechanism cancer therapy target.

Why it matters

Tumors need blood supply and immune evasion to grow. AM provides both. Blocking it could attack cancer from two directions simultaneously — an efficient therapeutic strategy.

How the study worked

Review of adrenomedullin expression in human cancers, its effects on tumor cell proliferation, angiogenesis, and immune modulation, with therapeutic targeting implications.

What this study cannot tell us

Review of early-stage cancer AM biology. The therapeutic potential of AM blockade in cancer was largely conceptual at the time.

How to read the evidence

Moderate evidence from a review synthesizing AM expression, functional, and mechanistic data across multiple cancer types.

When this study was published

Published in 2003. AM's role in cancer has been further confirmed, and AM-related biomarkers and therapies are being developed.

The bigger picture

Cancer exploits normal body systems for its benefit. AM's hijacking by tumors for blood supply and immune evasion exemplifies how cancer subverts physiology — and how blocking subverted systems can fight cancer.

Questions still open

• Could AM-blocking antibodies or receptor antagonists treat cancer?
• Which cancer types are most dependent on AM?
• Would AM blockade affect normal vascular function?

Common questions

Read the original research

Adrenomedullin and cancer.

Regulatory peptides, 112(1-3), 175-83

Citation

Zudaire, E; Martínez, A; Cuttitta, F. (2003). Adrenomedullin and cancer.. Regulatory peptides, 112(1-3), 175-83.